Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts give Maravai an average recommendation of Hold across seven analysts (1 sell, 3 hold, 3 buy) with a 12‑month average price target of about $4.86.
• Shares traded at $3.55 (52‑week range $1.66–$4.11) and the company reported quarterly EPS of ($0.04) beating estimates and revenue of $49.87M, but remains unprofitable with a negative net margin of 70.4% and an expected FY EPS of -0.24.
• Institutional investors have been adding stakes—large purchases by Monaco, General American, Millennium and others—and institutions now own roughly 50.25% of the stock.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) has earned an average recommendation of "Hold" from the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $4.8571.

A number of equities research analysts have weighed in on MRVI shares. Wall Street Zen upgraded Maravai LifeSciences from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Wells Fargo & Company upped their price objective on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an "overweight" rating in a report on Monday, December 15th.

Maravai LifeSciences Trading Up 1.4%

Shares of MRVI stock opened at $3.55 on Thursday. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $4.11. The business's fifty day moving average is $3.49 and its 200 day moving average is $3.27. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60. The company has a market capitalization of $907.76 million, a PE ratio of -3.94 and a beta of 0.38.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The business had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%. On average, equities research analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Monaco Asset Management SAM raised its position in shares of Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at approximately $7,670,000. General American Investors Co. Inc. raised its stake in Maravai LifeSciences by 1,062.2% during the fourth quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company's stock valued at $5,152,000 after buying an additional 1,448,907 shares during the last quarter. Tejara Capital Ltd boosted its holdings in Maravai LifeSciences by 257.8% in the second quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company's stock worth $4,679,000 after acquiring an additional 1,398,900 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Maravai LifeSciences by 308.7% in the fourth quarter. Millennium Management LLC now owns 1,797,052 shares of the company's stock worth $5,840,000 after acquiring an additional 1,357,349 shares in the last quarter. Institutional investors own 50.25% of the company's stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.